IMR Press / EJGO / Volume 28 / Issue 3 / pii/2007147

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Treatment results and prognostic factors for cervical cancer patients treated by radiochemotherapy with weekly cisplatin

Show Less
1 Department of Radiation Oncology, Ege University Medical School, Bornova Izmir, Turkey
Eur. J. Gynaecol. Oncol. 2007, 28(3), 196–200;
Published: 10 June 2007

Objective: This retrospective trial aims to report the treatment results of patients with locally advanced cervical cancer treated by concomitant radiochemotherapy with weekly cisplatin. Methods: Between October 1999 and December 2003, 81 patients with FIGO Stages IB-IVA were treated at Ege University Faculty of Medicine Department of Radiation Oncology by radiochemotherapy with weekly cisplatin (40 mg/m2). Intracavitary high­dose rate brachytherapy was applied to 76 patients (93.8%) and five patients (6.2%) were treated with external radiotherapy alone. Early and late side-effects of the treatment were analyzed according to RTOG-EORTC criteria. Results: Median age was 55 years and the most frequent histology was epidermoid carcinoma. Median follow-up time was 42 months. Five-year overall, disease-free and local relapse-free survival rates were 69%, 77%, and 82%, respectively. The presence of low Hgb level(< 12g/dl), bulky tumor(> 4 cm), poor performance status, pelvic nodal involvement and limited early response to treatment had a significant impact on the local failure rate. Prognostic factors influencing disease-free survival were bulky tumor, performance status, pelvic nodal status, pretreatment Hgb level and limited early response to treatment. A significantly higher 5- year overall survival rate was observed in patients with good performance status, without pelvic nodal involvement, normal pre­treatment Hgb level and complete response to treatment. Grade 3-4 side-effects were not observed in any patients. The most fre­quent acute side-effects were leukopenia, anemia, nausea and vomiting. Long-term side-effects were observed in 54% of patients. Conclusion: This series suggests that radiochemotherapy with weekly cisplatin is an effective and a safe treatment in locally advanced cervical cancer.

Cervical cancer
Prognostic factors
Back to top